|
Treatment-emergent adverse events (TEAEs) in lenalidomide (LEN)-treated Low-/Int-1-risk myelodysplastic syndromes (MDS) patients (pts) without del(5q) ineligible for or refractory to erythropoiesis-stimulating agents (ESAs). |
|
|
Honoraria - Celgene; Novartis |
Consulting or Advisory Role - Celgene; Novartis |
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Novartis; Shire |
Research Funding - Celgene |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - COTA |
|
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis |
Speakers' Bureau - Bristol-Myers Squibb; Novartis |
Research Funding - ARIAD; Astellas Pharma; Bristol-Myers Squibb; Celator; Celgene; Novartis; Pfizer |
Expert Testimony - Novartis |
Travel, Accommodations, Expenses - Pfizer |
|
|
Travel, Accommodations, Expenses - Takeda |
|
|
Research Funding - Celgene |
Travel, Accommodations, Expenses - Celgene |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Celgene |
Research Funding - Celgene |
|
|
Honoraria - Amgen; Celgene; Roche; Sunesis Pharmaceuticals |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
Honoraria - Celgene; Janssen; Novartis |
Research Funding - Celgene |